Eliem Therapeutics Files for IPO as Another Seattle-Area Biotech Firm Set to Go Public

Eliem Therapeutics, a Redmond, Washington based biotech company has filed for IPO. The filing follows two rounds of funding which took place earlier in 2021, raising $140M toward generating therapies nervous-system related conditions such as chronic pain and depression.

Eliem’s CEO Bob Azelby has years of experience leading other Washington based biotech companies such as Juno Therapeutics and Adler BioPharmaceutical, giving him the track record to join other biotech companies as the greater Seattle life sciences industry continues to grow.